⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for durvalumab

Every month we try and update this database with for durvalumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)NCT05620628
Stomach Cancer,...
Durvalumab
Savolitinib
19 Years - Samsung Medical Center
Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell CarcinomaNCT04054518
Esophageal Squa...
Durvalumab
18 Years - Instituto do Cancer do Estado de São Paulo
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerNCT05239169
Biliary Tract C...
Intrahepatic Ch...
Hilar Cholangio...
Distal Cholangi...
Gall Bladder Ca...
Durvalumab
Tremelimumab
Capecitabine
18 Years - Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerNCT04918186
Ovarian Cancer
Durvalumab
BA3011
BA3021
To be determine...
18 Years - Canadian Cancer Trials Group
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...NCT02484404
Colorectal Neop...
Breast Neoplasm...
Olaparib
Cediranib
Durvalumab
18 Years - National Institutes of Health Clinical Center (CC)
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerNCT02966587
Castration Leve...
Hormone-Resista...
Microsatellite ...
Durvalumab
Laboratory Biom...
18 Years - University of Washington
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297
Small Cell Lung...
Durvalumab
Tremelimumab
Placebo
18 Years - 130 YearsAstraZeneca
An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerNCT04089553
Prostate Cancer
Metastatic Cast...
AZD4635
Oleclumab
Durvalumab
18 Years - 130 YearsAstraZeneca
Durvalumab Long-Term Safety and Efficacy StudyNCT04078152
Solid Tumor
Durvalumab
18 Years - 130 YearsAstraZeneca
Using Circulating Tumor DNA to Personalize Duration of Consolidation DurvalumabNCT05757843
NSCLC, Stage II...
Signatera ctDNA...
Durvalumab
18 Years - Indiana University
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)NCT04255836
Carcinoma, Non-...
Durvalumab
the first line ...
stereotactic bo...
18 Years - 80 YearsZhejiang Cancer Hospital
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102
Triple Negative...
Durvalumab
Capivasertib
Oleclumab
Paclitaxel
Trastuzumab der...
Datopotamab der...
18 Years - 130 YearsAstraZeneca
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerNCT03237377
Non-Small Cell ...
Durvalumab
Tremelimumab
Thoracic Radiat...
lobectomy
Standard of car...
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTIONNCT04262375
Non Small Cell ...
Renal Cell Carc...
Durvalumab
Oleclumab
18 Years - University Health Network, Toronto
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaNCT02535078
Malignant Melan...
Tebentafusp (IM...
durvalumab
tremelimumab
18 Years - Immunocore Ltd
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomNCT04667312
Non-Small Cell ...
Durvalumab
18 Years - AstraZeneca
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.NCT04642469
Carcinoma, Non-...
Durvalumab
Placebo
18 Years - 130 YearsAstraZeneca
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderNCT05137262
Urothelial Carc...
Bladder Cancer
Abiraterone ace...
Durvalumab
Methotrexate
Vinblastine
Doxorubicin Hyd...
Cisplatin
18 Years - M.D. Anderson Cancer Center
Tumor Treating Fields for Locally Advanced NSCLCNCT06124118
Non Small Cell ...
carboplatin che...
NovoTTF-200T (T...
Durvalumab
22 Years - University of Utah
Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasNCT03283605
Head and Neck S...
Metastatic Squa...
SBRT
Durvalumab
Tremelimumab
18 Years - Centre hospitalier de l'Université de Montréal (CHUM)
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)NCT02775903
Leukemia, Myelo...
Myelodysplastic...
Azacitidine
Durvalumab
18 Years - Celgene
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerNCT05696782
Nonsmall Cell L...
Unresectable No...
Durvalumab
the EORTC Core ...
COPD Assessment...
Modified Medica...
18 Years - Wake Forest University Health Sciences
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on ChemotherapyNCT03007407
Colorectal Canc...
durvalumab
Tremelimumab
18 Years - NSABP Foundation Inc
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell LungNCT03589547
Stage III Non-s...
Durvalumab
SBRT
18 Years - Brown University
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775
Extensive Stage...
Stage IV Lung C...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Durvalumab
Echocardiograph...
Iadademstat
Magnetic Resona...
Multigated Acqu...
18 Years - National Cancer Institute (NCI)
TRUDI: TDXD+Durva in HER2+/Low IBCNCT05795101
Invasive Breast...
Inflammatory Br...
HER2-positive B...
HER2 Low Breast...
Breast Cancer
Trastuzumab der...
Durvalumab
18 Years - Dana-Farber Cancer Institute
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLCNCT04786093
Non Small Cell ...
Stereotactic ra...
Durvalumab
18 Years - University of Texas Southwestern Medical Center
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCCNCT03829007
Head and Neck C...
PD-L1 imaging
Durvalumab
18 Years - Radboud University Medical Center
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)NCT03830866
Locally Advance...
Durvalumab
Cisplatin
Carboplatin
external beam r...
18 Years - 130 YearsAstraZeneca
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung CancerNCT05903092
Small Cell Lung...
SCLC
Extensive Stage...
Durvalumab
Monalizumab
Carboplatin or ...
Etoposide
18 Years - Hoosier Cancer Research Network
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840
Non-Small Cell ...
Durvalumab
Oleclumab
Monalizumab
Placebo
18 Years - AstraZeneca
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerNCT04628767
Renal Pelvis an...
Biopsy
Biospecimen Col...
Cisplatin
Computed Tomogr...
Doxorubicin Hyd...
Durvalumab
Gemcitabine Hyd...
Magnetic Resona...
Methotrexate
Pegfilgrastim
Therapeutic Con...
Vinblastine Sul...
18 Years - National Cancer Institute (NCI)
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsNCT03737643
Advanced Ovaria...
Bevacizumab
Durvalumab
Olaparib
Placebo olapari...
Durvalumab plac...
Carboplatin+Pac...
18 Years - 130 YearsAstraZeneca
Durvalumab in Pediatric and Adolescent PatientsNCT02793466
Solid Tumor
Lymphoma
Central Nervous...
Durvalumab; MED...
1 Year - 17 YearsChildren's Hospital Los Angeles
SCION: SABR and Checkpoint Inhibition Of NSCLCNCT04944173
Non Small Cell ...
Carcinoma, Non-...
Non-small Cell ...
Lung Cancer
Lung Cancer Sta...
Lung Adenocarci...
Lung Squamous C...
Durvalumab
Stereotactic Bo...
Circulating Tum...
18 Years - University of British Columbia
Pilot Study of Durvalumab and Vigil in Advanced Women's CancersNCT02725489
Breast Cancer
Ovarian Cancer
Fallopian Tube ...
Primary Periton...
Uterine Cancer
Cervical Cancer
Endometrial Can...
Vigil
Durvalumab
18 Years - Mary Crowley Medical Research Center
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCNCT04543110
Bladder Cancer
Durvalumab
Immune Modulati...
18 Years - Ottawa Hospital Research Institute
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerNCT04699838
Extensive Stage...
Cisplatin
Carboplatin
Etoposide
Durvalumab
Ceralasertib
18 Years - Big Ten Cancer Research Consortium
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaNCT03959293
Gastric Adenoca...
Gastric Cancer
Durvalumab
Tremelimumab
FOLFIRI Protoco...
18 Years - Federation Francophone de Cancerologie Digestive
Study of Durvalumab and Guadecitabine in Advanced Kidney CancerNCT03308396
Advanced Kidney...
Kidney Cancer
Clear Cell Rena...
Guadecitabine
Durvalumab
18 Years - Big Ten Cancer Research Consortium
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskNCT05672537
Durvalumab
Intrahepatic Ch...
Gemcis
Durvalumab
Surgery
Gemcitabine
Cisplatin
18 Years - 75 YearsTianjin Medical University Cancer Institute and Hospital
......SMARTEST Trial......NCT05380713
Mesothelioma, M...
Cyclophosphamid...
Tremelimumab
Durvalumab
18 Years - 95 YearsUniversity Health Network, Toronto
Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)NCT05206812
Non Small Cell ...
durvalumab
20 Years - Yonsei University
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsNCT04361825
Small Cell Lung...
Durvalumab
18 Years - Samsung Medical Center
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)NCT03004105
Malignant Neopl...
Advanced Lung C...
Recurrent Nonsm...
Selumetinib
Durvalumab
Phone Calls
18 Years - M.D. Anderson Cancer Center
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaNCT02519348
Hepatocellular ...
Tremelimumab
Durvalumab
Bevacizumab
18 Years - 99 YearsMedImmune LLC
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOCNCT04644289
Epithelial Ovar...
olaparib
durvalumab
18 Years - AGO Research GmbH
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596
Gastric Cancer
Fluorouracil (5...
Capecitabine
Durvalumab
Oxaliplatin
Trastuzumab
Trastuzumab der...
Cisplatin
Pembrolizumab
Volrustomig
Rilvegostomig
18 Years - 130 YearsAstraZeneca
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.NCT05683977
Small Cell Lung...
durvalumab
- AstraZeneca
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsNCT03706690
Carcinoma, Non-...
Durvalumab
Placebo
18 Years - 130 YearsAstraZeneca
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerNCT03212469
Head and Neck S...
Lung Cancer
Oesophageal Can...
Durvalumab
Tremelimumab
SBRT
18 Years - Gustave Roussy, Cancer Campus, Grand Paris
Improve Checkpoint-blockade Response in Advanced Urothelial CancerNCT03871036
Urothelial Carc...
Tremelimumab
Durvalumab
Paclitaxel
18 Years - The Netherlands Cancer Institute
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.NCT06284317
Non Small Cell ...
Adjuvant durval...
18 Years - ETOP IBCSG Partners Foundation
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder CancerNCT05120622
Bladder Cancer
High-Risk Cance...
Tremelimumab
Durvalumab
Non-muscle Inva...
Tremelimumab
- University of British Columbia
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerNCT02888743
Metastatic Colo...
Metastatic Lung...
Stage IV Colore...
Stage IV Lung N...
Stage IVA Color...
Stage IVB Color...
Durvalumab
Radiation Thera...
Tremelimumab
18 Years - National Cancer Institute (NCI)
A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung CancerNCT04905316
Non-small Cell ...
Canakinumab
Durvalumab
Radiation thera...
Chemotherapy
18 Years - Memorial Sloan Kettering Cancer Center
RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in CanadaNCT05933044
Non-small Cell ...
Durvalumab
18 Years - 130 YearsAstraZeneca
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC RegimenNCT05443971
Lung Non-Small ...
Stage III Lung ...
Durvalumab
Radiation Thera...
Biospecimen Col...
18 Years - Mayo Clinic
Montreal Immune-Related Adverse Events (MIRAE) StudyNCT05139706
Cancer
Immune System D...
Inflammatory Re...
Autoimmune Dise...
18 Years - 100 YearsSir Mortimer B. Davis - Jewish General Hospital
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the BladderNCT02891161
Urothelial Canc...
durvalumab
Radiation Thera...
18 Years - Big Ten Cancer Research Consortium
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)NCT04989218
Cholangiocarcin...
Novel combinati...
18 Years - 89 YearsUniversity of Alabama at Birmingham
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue SarcomaNCT03116529
Soft Tissue Sar...
Combination Rad...
18 Years - University of Maryland, Baltimore
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerNCT04176848
Breast Cancer
CFI-400945
Durvalumab
18 Years - Canadian Cancer Trials Group
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsNCT03946800
Solid Tumors
Cancer
MEDI1191
Durvalumab
18 Years - 101 YearsMedImmune LLC
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaNCT04334759
Mesothelioma
Pleural Mesothe...
Malignant Pleur...
Durvalumab
Standard Chemot...
Ipilimumab and ...
18 Years - PrECOG, LLC.
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersNCT04230408
Lung Neoplasms
Durvalumab
18 Years - Latin American Cooperative Oncology Group
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaNCT03376659
Metastatic Colo...
Colorectal Aden...
Pancreatic Aden...
Metastatic Panc...
Durvalumab
CV301
Capecitabine
Bevacizumab
18 Years - Georgetown University
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction CancerNCT04592913
Gastrointestina...
Esophagogastric...
Durvalumab
FLOT chemothera...
18 Years - 200 YearsAstraZeneca
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast CancerNCT03740893
Breast Neoplasm
AZD6738
Olaparib
Durvalumab
18 Years - Institute of Cancer Research, United Kingdom
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic SarcomaNCT04668300
Metastatic Angi...
Metastatic Dedi...
Metastatic Oste...
Recurrent Angio...
Recurrent Dedif...
Recurrent Osteo...
Refractory Dedi...
Refractory Oste...
Durvalumab
Oleclumab
12 Years - M.D. Anderson Cancer Center
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerNCT04699838
Extensive Stage...
Cisplatin
Carboplatin
Etoposide
Durvalumab
Ceralasertib
18 Years - Big Ten Cancer Research Consortium
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsNCT04521686
Cholangiocarcin...
Chondrosarcoma
Glioma
Any Solid Tumor
LY3410738
Gemcitabine
Cisplatin
Durvalumab
18 Years - Eli Lilly and Company
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsNCT02900157
Advanced Solid ...
MEDI9090
Durvalumab
18 Years - 99 YearsMedImmune LLC
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerNCT05239169
Biliary Tract C...
Intrahepatic Ch...
Hilar Cholangio...
Distal Cholangi...
Gall Bladder Ca...
Durvalumab
Tremelimumab
Capecitabine
18 Years - Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297
Small Cell Lung...
Durvalumab
Tremelimumab
Placebo
18 Years - 130 YearsAstraZeneca
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerNCT04605731
BCLC Stage B He...
BCLC Stage C He...
Locally Advance...
Stage III Hepat...
Stage IIIA Hepa...
Stage IIIB Hepa...
Stage IV Hepato...
Stage IVA Hepat...
Stage IVB Hepat...
Unresectable He...
Durvalumab
Tremelimumab
18 Years - City of Hope Medical Center
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCNCT04765709
Non-small Cell ...
durvalumab plus...
Durvalumab plus...
durvalumab
18 Years - Mario Negri Institute for Pharmacological Research
Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based ChemotherapyNCT04800978
Cervical Cancer
BAVC-C+Durvalum...
19 Years - Samsung Medical Center
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCNCT03819465
Metastatic Non-...
Durvalumab
Danvatirsen
Oleclumab
MEDI5752
Pemetrexed
Carboplatin
Gemcitabine
Cisplatin
Nab-paclitaxel
AZD2936
18 Years - 130 YearsAstraZeneca
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer PatientsNCT02879617
Non-Small Cell ...
durvalumab
18 Years - Academic Thoracic Oncology Medical Investigators Consortium
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: